Document is current

Article History

Accepted: 13 February 2023

First Online: 25 February 2023

Declarations

:

: This study was approved by the Ethics Committee of Jena University Hospital (approval code 2021–2297) and adhered to the ethical principles of the 1964 Helsinki Declaration and its later amendments. The requirement for a documented informed consent was waived by the Ethics Committee in view of the retrospective nature of the study, and all the procedures being performed were part of the routine care.

: The authors declare the following potential conflicts of interest: J.S. received lecture fees and travel support from Falk Foundation, MSD, Shire, AbbVie, Pfizer, Janssen, and Bristol-Myers Squibb. P.C.G. obtained consulting fees from Janssen and Takeda and lecture fees and travel support from AbbVie, Janssen, Pfizer, Falk, and Takeda. K.L. received travel support from MSD. A.S. reports research funding from AbbVie and Celltrion and has received lecture fees from AbbVie, Amgen, Astellas, Biogen, Celltrion, Institut Allergosan, Janssen, Falk Foundation, Ferring, MSD, Recordati Pharma, Streamed-Up, and Takeda, and consulting fees from AbbVie, Astellas, Amgen, Biogen, CLS Behring, Consal, Galapagos, Hexal, Janssen, MSD, Norgine, Pfizer Pharma, Takeda, Pharmacosmos, and Tillots Pharma. A.S. is an Editorial Board Member of the International Journal of Colorectal Disease. Therefore, another Editor or Member of the Editorial Board was assigned to assume responsibility for overseeing peer review. This submission was subject to the exact same review process as any other manuscript. Editorial Board Members are welcome to submit papers to the journal. This submission was not given any priority over other manuscripts, and Editorial Board Member status had no bearing on editorial consideration. J.G., M.K., R.S., and V.E. report no conflicts of interest.